Orebro

• PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter … Recruiting
  2024-511053-22-00 4 2020-05-04 Primary sclerosing cholangitis (PSC)
• Does metformin reduce growth rate of small abdominal aortic aneurysms? Recruiting
  2024-517387-37-00 4 2019-12-12 Small abdominal aortic aneurysm (AAA) under active surveillance; 30-49
• Effects of an Opioid Sparing Care Pathway for Patients undergoing Obesity Surgery Recruiting
  2023-505934-86-00 6 2019-03-26 Obesity
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 5 2019-01-08 Prostate Cancer
• A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patient … Recruiting
  2023-504917-54-00 5 2018-10-30 Biochemical recurrence after prostate cancer surgery
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell … Ended recruitment
  2024-513539-25-00 4 2024-11-22 Type 2 Diabetes Mellitus
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• A randomized controlled trial with Rituximab for Psychotic disorder in adults Ended recruitment
  2024-512408-20-00 4 2024-08-27 Schizophrenia spectrum disorder (SSD)
• Intralymfatisk immunterapi förstärkt av vitamin-D, en randomiserad placebokontrollerad studie och jämförelse med SLIT Ended recruitment
  2024-515271-35-00 10 2023-02-01 Allergisk Rinit
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Ixekizumab Diabetes Intervention Trial (I-DIT) Ended recruitment
  2023-508588-58-00 4 2022-10-25 Diabetes type 1
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended recruitment
  2023-505255-51-00 5 2022-08-08 Herpes Zoster
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomised r … Ended recruitment
  2024-512453-25-00 6 2022-04-28 Rheumatoid arthritis
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, … Ended recruitment
  2024-512844-40-00 6 2021-04-20 Infertility
• Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Ended recruitment
  2023-504945-30-00 5 2021-03-16 Primary or recurrent non-muscle invasive bladder cancer with intermedi
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• NORTH-REG Dwell-Time Study Ended recruitment
  2023-505936-37-00 6 2021-02-03 Urothelial cancer
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early … Ended recruitment
  2022-501102-35-00 5 2019-12-02 Early triple negative breast cancer

Showing 73–96 of 129 trials